Strategic Blueprint’s Avanos Medical AVNS Stock Holding History

Strategic Blueprint’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3	Closed	–	–	470
2021 Q2	$0	Buy	+3	New	+$124	﹤0.01%	1412
2019 Q4	–	Sell	-3	Closed	–	–	116
2019 Q3	$0	Buy	+3	New	+$114	﹤0.01%	440

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Strategic Blueprint's AVNS Position: Q3 2021 in Review

Strategic Blueprint sold out of Avanos Medical (AVNS) in Q3 2021, closing a stake of 3 shares.

Strategic Blueprint first reported a position in AVNS in Q3 2019 and held it in 2 quarters. The position peaked at $0 in Q2 2021. 274 funds tracked by Wall St. Rank hold AVNS as of Q3 2021.

Strategic Blueprint reported no remaining Avanos Medical position as of Q3 2021 after selling out during the quarter.
Strategic Blueprint sold 3 Avanos Medical shares in Q3 2021.
Strategic Blueprint first reported a position in Avanos Medical in Q3 2019 and held it in 2 quarters.
Strategic Blueprint's Avanos Medical position peaked at $0 in Q2 2021.
274 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.